105 related articles for article (PubMed ID: 15600207)
1. [Technology optimization and properties study of factor IV complex concentrates].
Zeng R; Yu R; Li X; Wu Y; Qi H
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jan; 34(1):142-4. PubMed ID: 15600207
[TBL] [Abstract][Full Text] [Related]
2. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
3. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
4. Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Burnouf T; Michalski C; Goudemand M; Huart JJ
Vox Sang; 1989; 57(4):225-32. PubMed ID: 2617959
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
Limentani SA; Gowell KP; Deitcher SR
Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
[TBL] [Abstract][Full Text] [Related]
6. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
8. Factor IX concentrates .
Ménaché D
Thromb Diath Haemorrh; 1975 Jun; 33(3):600-5. PubMed ID: 1154314
[No Abstract] [Full Text] [Related]
9. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
[TBL] [Abstract][Full Text] [Related]
10. Immunopurification of human coagulation factor IX using monoclonal antibodies.
Bessos H; Prowse CV
Thromb Haemost; 1986 Aug; 56(1):86-9. PubMed ID: 3775693
[TBL] [Abstract][Full Text] [Related]
11. Large-scale preparation of thrombin from human plasma.
Aizawa P; Winge S; Karlsson G
Thromb Res; 2008; 122(4):560-7. PubMed ID: 18329699
[TBL] [Abstract][Full Text] [Related]
12. Application of monoliths for downstream processing of clotting factor IX.
Branović K; Buchacher A; Barut M; Strancar A; Josić D
J Chromatogr A; 2000 Dec; 903(1-2):21-32. PubMed ID: 11153943
[TBL] [Abstract][Full Text] [Related]
13. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates.
McLaughlin LF; Drummond O; MacGregor IR
Thromb Haemost; 1992 Nov; 68(5):511-5. PubMed ID: 1455396
[TBL] [Abstract][Full Text] [Related]
14. Purification of human factor IX by chromatography of a coagulation factor concentrate.
Suomela H
Thromb Haemost; 1976 Feb; 35(1):211-21. PubMed ID: 989188
[TBL] [Abstract][Full Text] [Related]
15. The isolation of prothrombin, Factor IX and Factor X from human Factor IX concentrates.
Modi GJ; Blajchman MA; Ofosu FA
Thromb Res; 1984 Dec; 36(6):537-47. PubMed ID: 6084874
[TBL] [Abstract][Full Text] [Related]
16. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
17. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
[TBL] [Abstract][Full Text] [Related]
18. Factor IX concentrates for clinical use.
Thompson AR
Semin Thromb Hemost; 1993; 19(1):25-36. PubMed ID: 8456321
[No Abstract] [Full Text] [Related]
19. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
Ikematsu S; Yorifuji H; Arai M; Fukutake K
Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
[No Abstract] [Full Text] [Related]
20. Heat treatment at 100 degrees C of factor VIII and IX coagulation factor concentrates.
Teh LC; Woodfield DG
Med J Aust; 1993 Sep; 159(5):355-6. PubMed ID: 8361441
[No Abstract] [Full Text] [Related]
[Next] [New Search]
